← Back to feedRead original →
VERIFIEDET Finance·neutral
Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial
AI Summary
- ·Zydus Lifesciences announced its drug Saroglitazar Magnesium achieved its primary objective in a global Phase II(b) trial.
- ·The trial focused on MASH, a severe liver condition associated with metabolic disorders.
- ·Saroglitazar Magnesium is being tested for its efficacy in treating MASH.